Business context and reporting period
Gyrodyne, LLC filed this Form 10-Q for the quarter ended September 30, 2016. The company is liquidating its real estate portfolio and uses liquidation-basis accounting; its financial statements therefore present net assets and changes in net assets rather than conventional operating results.
Key financial metrics
| Metric | September 30, 2016 | December 31, 2015 |
|---|---|---|
| Real estate held for sale | $28.91 million | $46.95 million |
| Cash and cash equivalents | $4.21 million | $5.88 million |
| Marketable securities | $4.45 million | $5.00 million |
| Total assets | $37.67 million | $57.89 million |
| Total liabilities | $9.66 million | $14.44 million |
| Net assets in liquidation | $28.01 million | $43.46 million |
Net assets equated to estimated liquidation value of approximately $18.89 per share at September 30. The filing reports no debt balance. Cash flow and conventional profit or margin figures are not provided under the liquidation-basis presentation.
Changes and operating activity
- Net assets increased by $491,628 from real estate and securities valuation changes and remeasurement, then declined by $15.94 million of liquidating distributions, resulting in a net decrease of $15.45 million for the nine months.
- The company sold Fairfax Medical Center for $14.015 million and five Port Jefferson buildings for aggregate gross proceeds of $4.246 million. It also acquired an adjacent four-acre lot for approximately $210,000.
- Special distributions were $9.25 per share in June and $1.50 per share in September.
- Third-quarter rental revenue was $739,050. Portfolio occupancy was 73%, down from 78% at December 31, 2015; average effective rent was $16.99 per square foot versus $19.52. Portfolio changes, including property sales, affect these comparisons.
- For the nine months, the company reported 25 lease renewals, two expansions and nine new leases, offset by eight terminations. Lease commitments were approximately $6.03 million at September 30, down from $16.04 million at year-end, primarily reflecting property sales.
Outlook, risks and unusual items
Management expects to complete liquidation by the end of 2018, but timing and proceeds are uncertain. It estimates approximately $28 million of net assets at liquidation before future distributions, equivalent to the stated $18.89 per-share estimate. This estimate excludes potential additional value from entitlement efforts and is not a guarantee of distributions.
The company expects approximately $3.15 million of land-development and entitlement costs for Flowerfield and Cortlandt Manor; approximately $770,000 had been incurred through September 30. Its strategy is to pursue zoning and other approvals to enhance sale value, not to develop the properties. Entitlements depend on municipal decisions, and costs, timing and sale values may differ materially from estimates.
Other risks include local real estate conditions, leasing and tenant credit, interest rates and financing availability, potential claims and liquidation expenses. Fairfax carries a company-guaranteed master-lease obligation; the estimated remaining balance was approximately $50,593. The company also disclosed $677,100 of employment and severance contingencies. A shareholder class action settlement was approved in April 2016; the company paid $650,000 in fees and expenses and received approximately $399,000 from its D&O insurer.
Important facts for investors to verify
- Whether actual property-sale proceeds, entitlement outcomes and liquidation costs support the $18.89-per-share estimate.
- The timing and amount of future distributions, including the impact of remaining liabilities, contingencies and retention bonuses.
- Occupancy, rent levels, lease renewals and tenant incentives across the remaining properties.
- Progress and spending on Flowerfield and Cortlandt Manor approvals, and whether these efforts produce value beyond amounts reflected in reported net assets.
- The collectability, if any, of a potential distribution from the distressed Callery Judge Grove partnership; the investment is carried at zero.